Suppr超能文献

谁接受华法林抗凝治疗,以及为什么?芬兰的一项基于人群的研究。

Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland.

机构信息

Department of General Practice, University of Tampere, Hospital District of South Ostrobothnia, Finland.

出版信息

Scand J Prim Health Care. 2010 Dec;28(4):237-41. doi: 10.3109/02813432.2010.514138. Epub 2010 Sep 7.

Abstract

OBJECTIVE

To ascertain the age and gender distribution of patients receiving anticoagulant (AC) treatment with warfarin, and to establish the prevalence of AC treatment and its indications among the Finnish population.

DESIGN

A cross-sectional study in which the patients were identified from the patient records of health centres.

SETTING

Primary health care in the Hospital District of South Ostrobothnia in Finland.

PATIENTS

Those inhabitants of 15 municipalities in the study area who received AC treatment with warfarin on 1 April 2004. The total number of inhabitants was 132 621 at the end of 2003.

MAIN OUTCOME MEASURES

Patient age and gender distributions, the prevalence of AC treatment in the study area, and indications for AC treatment.

RESULTS

Altogether 2389 patients were identified, 51.4% of them men. The mean age of the patients was 72.4 years. The prevalence of AC treatment was 1.8%; when age-adjusted to match the Finnish population it was 1.64%. The proportion of men receiving AC treatment was higher than that of women in all age groups. Atrial fibrillation (AF) was the most common main (60.2%) and second (7.2%) indication for AC treatment.

CONCLUSION

Compared with Finnish figures 12 years earlier the prevalence of AC treatment has more than doubled, and the proportion of AF among indications has increased from 47% to 67%. New current care guidelines on AF and the increasing proportion of the elderly among the population are probable explanations.

摘要

目的

确定接受华法林抗凝(AC)治疗的患者的年龄和性别分布,并确定芬兰人群中 AC 治疗的流行率及其适应证。

设计

一项横断面研究,通过健康中心的患者记录确定患者。

设置

芬兰南奥斯特罗波的尼亚区的初级保健。

患者

2004 年 4 月 1 日在研究区域内接受华法林 AC 治疗的 15 个市的居民。2003 年底,该研究区域的居民总数为 132621 人。

主要观察指标

患者年龄和性别分布、研究区域内 AC 治疗的流行率以及 AC 治疗的适应证。

结果

共确定了 2389 名患者,其中 51.4%为男性。患者的平均年龄为 72.4 岁。AC 治疗的流行率为 1.8%;年龄调整后与芬兰人口的流行率为 1.64%。在所有年龄组中,接受 AC 治疗的男性比例均高于女性。心房颤动(AF)是 AC 治疗的最常见的主要(60.2%)和次要(7.2%)适应证。

结论

与 12 年前的芬兰数据相比,AC 治疗的流行率增加了一倍以上,AF 在适应证中的比例从 47%增加到 67%。新的当前 AF 护理指南和人口中老年人比例的增加可能是其原因。

相似文献

2
Anticoagulant treatment in primary health care in Finland.芬兰初级卫生保健中的抗凝治疗。
Scand J Prim Health Care. 1996 Sep;14(3):165-70. doi: 10.3109/02813439609024172.
6
Are atrial fibrillation guidelines altering management? A community based study.
Scott Med J. 2005 Nov;50(4):166-9. doi: 10.1177/003693300505000409.

引用本文的文献

3
Building a primary care research network - lessons to learn.建立基层医疗研究网络——可吸取的经验教训。
Scand J Prim Health Care. 2017 Sep;35(3):229-230. doi: 10.1080/02813432.2017.1358439. Epub 2017 Aug 28.
8
Reversal of anticoagulant effects in patients with intracerebral hemorrhage.脑出血患者抗凝作用的逆转。
Curr Neurol Neurosci Rep. 2015 Jan;15(1):504. doi: 10.1007/s11910-014-0504-2.

本文引用的文献

2
Dabigatran versus warfarin in patients with atrial fibrillation.达比加群与华法林用于房颤患者的比较。
N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
3
[Rivaroxaban (Xarelto): efficacy and safety].利伐沙班(拜瑞妥):疗效与安全性
Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S22-7. doi: 10.1016/S0750-7658(08)75143-8.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验